Should the patient start testosterone replacement therapy (TRT) before a polysomnography sleep study when the hematocrit is 56%?

No, Do Not Start Testosterone Replacement Therapy with a Hematocrit of 56%

A hematocrit of 56% is an absolute contraindication to initiating testosterone replacement therapy and requires immediate evaluation for underlying causes of polycythemia before any consideration of TRT. The patient needs a sleep study and treatment of any identified sleep apnea before TRT can be safely considered.

Why This Hematocrit Level Prohibits TRT Initiation

The Endocrine Society guidelines explicitly state that if hematocrit exceeds 54%, therapy must be stopped until hematocrit decreases to a safe level 1, 2. Your patient's hematocrit of 56% already exceeds this threshold by 2 percentage points. The 2010 guidelines further clarify that baseline hematocrit above 50% is a relative contraindication to testosterone therapy because these men are more likely to develop hematocrit >54% when treated with testosterone 2. The 2018 update reinforces that baseline hematocrit >48% (>50% for men at higher altitudes) is a relative contraindication 3.

Starting TRT at a hematocrit of 56% would:

• Further increase an already dangerously elevated hematocrit (testosterone causes dose-dependent erythrocytosis 2, 4)
• Increase blood viscosity and thrombotic risk
• Potentially precipitate cardiovascular events

The Critical Sleep Apnea Connection

The guidelines specifically mandate that when hematocrit is elevated, clinicians must "evaluate the patient for hypoxia and sleep apnea" before any consideration of reinitiating therapy 1, 2, 3. This is not optional—it's a required step in the algorithm.

Here's why this sequence matters:

Sleep apnea independently causes polycythemia through chronic intermittent hypoxia, which stimulates erythropoietin production 5, 6. The relationship is bidirectional and synergistic:

• Untreated OSA causes secondary polycythemia
• TRT can worsen OSA symptoms 5
• The combination of OSA and TRT dramatically increases polycythemia risk (odds ratio 2.09 even after adjusting for age, BMI, and testosterone levels) 6
• Men with both OSA and TRT have a hazard ratio of 7.4 for developing erythrocytosis compared to cisgender men 7

The Correct Clinical Algorithm

1. Immediately defer TRT initiation due to hematocrit 56%

2. Order polysomnography (sleep study) to evaluate for obstructive sleep apnea

   • This is mandatory per guidelines when hematocrit is elevated 1, 2
   • Also evaluate for other causes of hypoxia (chronic lung disease, high altitude residence)

3. If OSA is diagnosed:

   • Initiate CPAP or other appropriate OSA treatment
   • TRT remains contraindicated until OSA is adequately treated 8
   • Monitor hematocrit response to OSA treatment alone

4. Reassess hematocrit after OSA treatment:

   • Wait for hematocrit to decrease to <50% (ideally <48%)
   • This may take several months with effective OSA therapy
   • If hematocrit normalizes with OSA treatment alone, the patient may not have had true hypogonadism

5. Only after hematocrit normalizes and OSA is controlled:

   • Reconfirm hypogonadism diagnosis (two morning fasting testosterone measurements)
   • Consider TRT initiation with close monitoring
   • Use transdermal formulations preferentially (lower erythrocytosis risk than injections 4, 9)
   • Check hematocrit at 3 months, then every 6-12 months 3

Common Pitfalls to Avoid

Do not rationalize starting TRT despite elevated hematocrit. Some clinicians might consider using lower doses or transdermal preparations, but the guidelines are clear: elevated baseline hematocrit is a contraindication that must be addressed first 2, 3.

Do not skip the sleep study. The FDA label for testosterone explicitly lists the need to evaluate for sleep apnea when polycythemia develops 10. This patient already has polycythemia before starting therapy, making the evaluation even more critical.

Do not assume the elevated hematocrit is "just" from dehydration or lab error. A hematocrit of 56% represents true polycythemia that requires investigation. Repeat the test if needed, but proceed with the sleep study regardless.

Recognize that untreated severe OSA is an absolute contraindication to TRT 8. Even if the patient is eager to start testosterone, doing so with untreated OSA and elevated hematocrit creates unacceptable cardiovascular risk.

Risk Stratification

The patient's elevated hematocrit suggests either:

• Undiagnosed obstructive sleep apnea (most likely given the clinical context)
• Chronic hypoxia from another cause
• Primary polycythemia vera (less likely but must be excluded)
• Chronic lung disease
• High altitude residence

Each of these requires specific management before TRT can be safely initiated. The sleep study is the essential first step in this evaluation.